Imurek (Azathioprine)

Azathioprine is a purine analog that is metabolized to 6‑mercaptopurine nucleotides inside cells. These metabolites become incorporated into DNA and RNA, disrupting nucleic acid synthesis and preventing the proliferation of rapidly dividing immune cells, especially T and B lymphocytes, thereby reducing immune‑mediated inflammation.

The appropriate dose of Imurek is individualized by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and concurrent therapies. Dosage adjustments are guided by regular laboratory monitoring of blood counts and liver enzymes to balance efficacy with safety.

Safety of azathioprine in pregnancy and lactation is assessed case by case. While some data suggest limited placental transfer, the drug is generally avoided unless the therapeutic benefit outweighs potential risks. Breastfeeding mothers should discuss continuation with their healthcare provider, as azathioprine can be excreted in milk.

To order Imurek, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the request, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details and any required import documentation.

Both azathioprine (Imurek) and mycophenolate mofetil are antimetabolite immunosuppressants used in transplant and autoimmune settings. Azathioprine interferes with purine synthesis via 6‑mercaptopurine, while mycophenolate blocks inosine monophosphate dehydrogenase. Their side‑effect profiles differ; azathioprine is more associated with bone‑marrow suppression, whereas mycophenolate commonly causes gastrointestinal upset. Choice depends on patient tolerance, comorbidities and physician preference.

Imurek tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the container tightly closed and out of reach of children. Do not store in humid areas such as bathrooms, and discard any tablets that appear discolored or damaged.

Imurek is taken orally, usually with food or a glass of water to reduce gastrointestinal irritation. The exact dosing schedule—once daily or divided doses—depends on the prescribing clinician’s recommendation. Patients should follow the prescribed regimen precisely and not alter the dose without medical advice.

The most serious risks include severe bone‑marrow suppression leading to pancytopenia, significant hepatotoxicity, opportunistic infections due to immunosuppression, and an increased long‑term risk of certain malignancies such as lymphoma or skin cancer. Prompt reporting of symptoms like fever, persistent fatigue, jaundice or unusual bruising is essential.

Imurek is contraindicated in patients with known hypersensitivity to azathioprine or any of its excipients, those with active, uncontrolled infections, and individuals with severe hepatic impairment. Caution is also advised for patients with pre‑existing bone‑marrow disorders, pregnant or nursing women unless the benefits clearly outweigh the risks, and anyone taking interacting medications without proper monitoring.